Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25437981 | 0.92 | LMNA (0.59) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL30585033 | 0.92 | LMNA (0.59) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31546344 | 0.91 | MEN1 (0.55) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31546367 | 0.91 | POLB (0.60) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31546397 | 0.91 | MEN1 (0.60) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31546325 | 0.90 | MEN1 (0.59) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31667355 | 0.89 | LMNA (0.58) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31546420 | 0.87 | MEN1 (0.57) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31546360 | 0.87 | MEN1 (0.57) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL30584881 | 0.87 | MEN1 (0.59) | LMNAMEN1KMT2ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | LMNA 1344/4885MEN1 1569/4885KMT2A 1404/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | LMNA 1344/4885MEN1 1569/4885KMT2A 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.